A randomised crossover trial of daridorexant for the treatment of chronic insomnia and nocturia

Journal of Sleep Research, Journal Year: 2025, Volume and Issue: unknown

Published: March 13, 2025

Summary This double‐blind, placebo‐controlled, two‐way crossover trial evaluated the efficacy and safety of daridorexant in patients with chronic insomnia comorbid nocturia. In total, 60 aged ≥55 years complaints for ≥3 months, Insomnia Severity Index (ISI) ≥13 voids/night ≥1 month were randomised (1:1) to 50 mg/placebo 4 weeks followed by after a 14–21‐day washout period. The primary endpoint was change from baseline Week (W) self‐reported total sleep time (sTST). Other endpoints included ISI score, depth quality (visual analogue scale scores), nocturnal voids (mean number, first) daytime functioning (Insomnia Daytime Symptoms Impacts Questionnaire score [IDSIQ]). At W4, significantly increased sTST versus placebo (least‐squares mean difference [LSMD] 20.9 min, 95% confidence interval [CI] 8.0–33.7; p = 0.002); significant improvements also seen at W1–3. Compared placebo, decreased ( < 0.001) both timepoints, W2 (LSMD −3.7, CI −5.1 −2.3) W4 −3.3, −4.7 −1.8) improved 0.05) (W1, 2, 3, 4), 3) IDSIQ 3). Daridorexant reduced number [95% CI]: W1–0.6 [−0.9 −0.3], 0.001; W4–0.3 [−0.7 +0.1], 0.090) median first void (difference W1: +31 0.0027; W4: +23 0.2026). No adverse events special interest (falls/urinary incontinence) reported during treatment. conclusion, nocturia, improves conditions favourable profile.

Language: Английский

---

The Chronobiological and Neuroprotective Mechanisms of Resveratrol in Improving Sleep

Mediators of Inflammation, Journal Year: 2025, Volume and Issue: 2025(1)

Published: Jan. 1, 2025

According to statistics, more than one‐third of the global population currently experiences sleep problems, and about 10% adults have been diagnosed with insomnia, a proportion that is increasing annually. Most used insomnia medications are not specifically developed but discovered by chance, often resulting in unavoidable side effects like addiction. Thus, there an urgent need find safer effective therapeutic options. Resveratrol, natural polyphenolic compound, shows significant potential improving insomnia. Research its may be achieved through multiple biological processes, including antiapoptosis, antioxidant activity, anti‐inflammation, circadian rhythm regulation, modulation neurotransmitters (gamma‐aminobutyric acid (GABA), DA, 5‐HT, cortisol), increased levels neurotrophic factor BDNF. Additionally, resveratrol’s treatment closely linked SIRT1, AMPK, NF‐ κ B, mTOR, PI3K/Akt, MAPK pathways. This review summarizes mechanisms resveratrol treating provide researchers deeper understanding action, which can aid development novel targeted drugs offer innovative ideas methods for clinical treatment.

Language: Английский

---

The Critical Role of Sleep in Enhancing Pulmonary Rehabilitation Outcomes

Seminars in Respiratory and Critical Care Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Abstract Pulmonary rehabilitation is a comprehensive, interdisciplinary intervention that aims to enhance the physical and psychological well-being of individuals with chronic respiratory diseases. This approach entails implementation tailored therapies, including exercise training, education, behavioral modification. Sleep plays crucial role in numerous physiological processes, regulation inflammation tissue repair, both which are fundamental efficacy rehabilitation. A paucity optimal sleep health has been associated deleterious effects on pivotal factors indispensable for favorable outcomes pulmonary rehabilitation, mental immune function. This, turn, may increase susceptibility impaired The integration protocols healthy practices expected yield significant improvements lung function overall health, will, promote long-term adherence rehabilitative behaviors. study examine relationship between outcomes.

Language: Английский

---

Sex and age differences in sleep disorders: insights from a diverse cohort referred to a sleep center

Neurological Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: April 4, 2025

Language: Английский

---

EEG spectral analysis of nighttime sleep and daytime MSLTs and neurocognitive evaluations in subjects with co-morbid insomnia and OSA

Respiratory Research, Journal Year: 2025, Volume and Issue: 26(1)

Published: April 13, 2025

Chronic insomnia and obstructive sleep apnea commonly co-occur. Few studies have explored the neurophysiological neurocognitive characteristics of COMISA, which could help guide improving treatment diagnostic tools determining novel therapeutic targets. This study aims to explore COMISA using electroencephalographic (EEG) spectral analysis subjective objective measurements. Participants were from our community recruited OSA-insomnia-COMISA cohort with 206 included for current including 74 chronic insomniacs (CIs), 55 OSA patients 77 patients. Standard polysomnography (PSG) multiple latency tests (MSLTs) recorded used obtain relative EEG power in each stage during PSG session MSLTs. A series conducted evaluate executive function, attention, retrospective prospective memory meta-cognition. In MSLTs, showed combined both CIs OSA. Specifically, exhibited similar CIs, decreased delta increased alpha beta NREM stages, REM Similar profile OSA, Compared patients, worse subjectively measured attention meta-cognition related negative beliefs about uncontrollability danger worry (NEG), positively associated ISI scores. The overnight daytime MSLT appear be manifestation elements However, features NEG primarily affected by insomnia.

Language: Английский

---